CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 117 enrolled
Drug / intervention
galantaminedrug
Likely dose
Not stated in record
Key inclusion· 4
  • ✓DSM-IV diagnosis of schizophrenia or schizoaffective disorder
  • ✓Age 18–60 years
  • ✓Currently treated with one of: olanzapine, risperidone, quetiapine, ziprasidone, or aripiprazole
  • ✓Cognitive impairment with RBANS total score ≤90 (one standard deviation below normal control mean)
Key exclusion· 6
  • ✕History of organic brain disease
  • ✕DSM-IV alcohol or substance abuse within the last month, or dependence within the last six months
  • ✕Pregnant women or women taking oral contraceptives
  • ✕Current treatment with galantamine or other acetylcholinesterase inhibitor (e.g. donepezil)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00176423
NCT00176423Phase 4Completed
CompareCT.gov

Adjunctive Galantamine for Treatment of Cognitive Impairments in Patients With Schizophrenia

University of Maryland, Baltimore·interventional·Posted Sep 15, 2005·Updated Dec 16, 2020

In Brief

A Phase 4 clinical trial evaluating galantamine for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 117 participants across 1 site.

Detailed Summary

The purpose of this study is to examine whether adjunctive galantamine is effective in the treatment of cognitive impairments in patients with schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
CollaboratorsStanley Medical Research Institute, Ortho-McNeil Neurologics, Inc.

Timeline

Phase 4CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 15, 2005
Enrollment StartMay 1, 2002
Primary CompletionDec 1, 2006
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 20.8 years ago

Interventions

galantaminedrug

see arm/group description